NCT01096511 - Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI) | Biotech Hunter

Enrollment

1,001

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Secondary PeritonitisAbscess, Intra-Abdominal

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.

Trial Locations (1)

Unknown

Many Locations